Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sofosbuvir Patent Challenge Could Highlight Weaknesses In IP Systems

Executive Summary

NGOs from across Europe are challenging a patent protecting Gilead’s Sovaldi in an effort to expand patient access to hepatitis C treatments. They say the case will also expose failings in the intellectual property rights system that hinder access to innovation.

You may also be interested in...



NGOs Continue Fight To Remove Key Patent On Gilead’s Sovaldi

NGOs are continuing their efforts to pave the way for lower-cost generic versions of Gilead’s breakthrough hepatitis C treatment Sovaldi and have appealed a decision by the European Patent Office to uphold a key patent relating to the drug.

European Patent Office Upholds Gilead’s Sofosbuvir Patent

A challenge brought to the European Patent Office that sought to open the door to generic competition to Gilead’s hepatitis C treatment has failed.

Transparency, IP Issues Dominate Discussion On WHO's Roadmap To Improve Drug Access

Advocacy groups want the WHO's proposed roadmap on improving access to medicines to include stronger language on transparency of R&D costs, prices and revenues. The pharmaceutical industry, however, believes any forward-looking solution should rest upon strong IP protection.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel